Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For medical device manufacturers based outside the European Union, selecting an EU Authorized Representative (AR) is a critical step for market access under the Medical Device Regulation (MDR). Beyond...
When selecting an EU Authorized Representative (AR) under the Medical Device Regulation (MDR), what specific criteria should non-EU manufacturers use to evaluate potential partners beyond basic regist...
When non-EU manufacturers budget for compliance with the Medical Device Regulation (MDR), the cost of an EU Authorized Representative (AR) is a significant consideration that extends beyond a simple a...
For foreign cosmetic establishments required to appoint an FDA U.S. Agent under the Modernization of Cosmetics Regulation Act (MoCRA), how can the total cost and value of this service be evaluated bey...
What are the primary factors that determine the annual cost of retaining an FDA U.S. Agent, and how can foreign establishments differentiate between a basic service agreement and a more comprehensive ...
Foreign medical device establishments are required to designate a U.S. Agent to serve as their official point of contact with the FDA. With the new Quality Management System Regulation (QMSR) becoming...
When evaluating "Person Responsible for Regulatory Compliance (PRRC) as a Service" under the EU MDR, how can manufacturers move beyond a simple price tag to accurately assess the total cost and value?...
For medical device startups navigating the European market, appointing a Person Responsible for Regulatory Compliance (PRRC) is a mandatory requirement under EU MDR Article 15. Given that hiring a ful...
As medical device manufacturers plan their compliance strategies for 2026 and beyond, how can they develop a robust framework for selecting an external 'Person Responsible for Regulatory Compliance (P...
When a non-EU manufacturer seeks to appoint a REACH Only Representative (OR) to comply with Regulation (EC) No 1907/2006 (REACH), what comprehensive framework of due diligence should be employed to en...
With the ECHA Forum announcing a pilot project in 2026 to inspect the compliance of Only Representatives (ORs), how should non-EU manufacturers of chemical substances re-evaluate their selection proce...
For sponsors developing a novel Class II in vitro diagnostic (IVD), such as a pharmacogenetic assessment system or a mass spectrometry-based test, what are the key factors in determining the necessary...
For non-EU medical device manufacturers, what is the role and strategic importance of the European Authorised Representative (AR) under the EU Medical Device Regulation (MDR), and what key qualificati...
When are Special Controls required for a Class II medical device, and how do they build upon General Controls to ensure safety and effectiveness? All medical devices marketed in the U.S. are subject ...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic product manufacturers and processors face a new critical requirement: appointing a United States Agen...
For foreign cosmetic establishments, the Modernization of Cosmetics Regulation Act (MoCRA) introduces a mandatory requirement to designate a United States Agent. But beyond fulfilling a line item on a...
When budgeting for 2025, how can medical device manufacturers effectively evaluate the true cost and value of outsourcing the Person Responsible for Regulatory Compliance (PRRC) role? Beyond a standar...
When evaluating external providers for the Person Responsible for Regulatory Compliance (PRRC) role under the EU Medical Device Regulation (MDR), manufacturers often discover that the cost is not a si...
For non-EU medical device manufacturers, navigating the complexities of the EU REACH regulation for substances like Per- and Polyfluoroalkyl Substances (PFAS) presents a significant compliance challen...
With the European Chemicals Agency (ECHA) planning targeted inspections of Only Representatives (ORs) in 2026 under its REF-14 enforcement project, how can non-EU manufacturers move beyond a simple ch...